High blood sugar is silently affecting blood vessels across the Nordic region, and most individuals remain unaware. While Sweden’s alarming prediabetes statistics have garnered attention, the issue extends far beyond the country’s borders. As of 2024, 635 million adults globally are living with impaired glucose tolerance (IGT), reflecting a rise in global prevalence from 9.1% to 12.0% since 2021. This condition has become one of the most significant yet overlooked threats to both public health and economic productivity across the Nordics and the world.
For businesses in the Nordic region, the repercussions of this “silent epidemic” are far-reaching, ranging from escalating healthcare costs to lost productivity. Furthermore, the emergence of new regulatory frameworks could reshape corporate wellness obligations. This article explores the current state of prediabetes in the Nordics, evaluates the region’s policy responses, and highlights the critical gaps that need urgent attention from both policymakers and business leaders.
The Nordic Context: A Regional Challenge
Recent data from Sweden paints a concerning picture. Between 2006 and 2021, the prevalence of Type 2 diabetes (T2D) increased from 4.87% to 7.50%, with early-onset cases (ages 23–39) nearly doubling during this period. Projections suggest that if these trends continue, early-onset T2D could affect 3.2% of the population by 2050, a fivefold increase from 2021 levels.
However, framing the issue as merely a Swedish phenomenon overlooks the broader Nordic reality. Despite Europe having the lowest age-standardized prediabetes rates globally (compared to regions like Southeast Asia), the absolute numbers are still concerning. In the neighbouring Netherlands, 1.3 million people are estimated to have prediabetes, many of whom remain unaware of their condition. European studies consistently reveal that one-third of people with diabetes are undiagnosed, and prediabetes awareness is even lower.
In the Nordic region, this paradox is particularly striking. Despite universal healthcare systems and high health literacy rates, the region faces the same awareness gaps seen in other parts of the world. In Stockholm County, 54% of individuals with T2D were undiagnosed at the end of the first follow-up period in a major study, with that number improving only to 43.5% in later years. This continues to highlight a significant diagnostic gap.
The Business Case: Economic Impact Beyond Healthcare
The economic argument for addressing prediabetes extends far beyond medical expenses. Cardiovascular disease (CVD), closely linked to prediabetes and diabetes, costs the EU €282 billion annually, equivalent to 2% of its GDP. This includes:
- Healthcare costs: €130 billion (46% of total costs)
- Informal care: €79 billion (28%)
- Productivity losses: €47 billion (17%)
- Social care: €25 billion (9%)
Additionally, diabetes-related productivity losses in the EU add another €65 billion annually, with a significant portion of healthcare costs driven by avoidable complications. In the U.S., employees with Type 2 diabetes experience 4.2 excess days lost annually, with productivity costs 13.3% higher and medical costs twice as high as their non-diabetic counterparts.
For Nordic businesses, these figures translate to tangible impacts:
- Absenteeism and presenteeism: Workers with prediabetes often exhibit reduced cognitive function and energy levels, even before a formal diagnosis.
- Healthcare expenditures: Nordic employers typically shoulder substantial portions of healthcare costs through occupational health systems.
- Talent retention: Early-onset metabolic diseases disproportionately affect working-age populations, threatening workforce sustainability.
The progression of cardio diabesity—a syndrome that includes cardiovascular disease, diabetes, and obesity—presents a particularly concerning pattern. Research indicates that 27.4% of patients with early-stage cardio diabesity progress to active disease within one year, and once the disease becomes active, 88.4% progress to complications within the same period, driving substantial cost increases at every phase.
Current Policy Landscape: Nordic Leadership and Emerging Gaps
Finland: A Pioneering Approach
Finland is leading the charge in prediabetes prevention within the Nordic region. The DEHKO program (2000–2010) and its successor, FIN-D2D (2003–2008), were the world’s first large-scale T2D prevention initiatives. Key elements of the Finnish model include:
- FINDRISC screening tool: A non-laboratory risk assessment tool now widely used across both primary and occupational healthcare settings.
- Lifestyle interventions: Participants who achieved a 5% weight loss saw a 69% reduction in diabetes risk, with even modest weight loss providing significant benefits.
- Long-term impact: A 30% risk reduction for those who received drug treatment, sustained over 7.4 years.
- Population awareness: The program successfully reached 48% of women and 25% of men, leading to significant behavioral change.
Despite these successes, post-program surveillance reveals a drop in new glucose-lowering drug reimbursements after 2010, reflecting improved screening but also showing the need for continuous intervention.
Sweden: Improving but Lagging
Sweden’s approach has primarily focused on high-risk screening within primary care settings, targeting individuals with hypertension, obesity, and other risk factors. However, undiagnosed T2D remains a significant issue, especially among those without obvious risk factors. The 2024 European Parliament resolution on diabetes prevention and Sweden’s involvement in the EU Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), a €53 million initiative, highlight Sweden’s increasing commitment to the cause.
Norway and Denmark: Building Momentum
Norway’s 2019 strategy focused on non-communicable diseases (NCDs), which included prediabetes prevention through risk factor management, including physical activity promotion, taxation, and regulation. Denmark, while less documented, is participating in EU initiatives like JACARDI and EU4Health, providing platforms for further action.
EU-Level Developments
At the European level, significant shifts are underway:
- 2024 European Parliament resolution: A historic call for stronger actions on diabetes prevention and care.
- WHO Europe/IDF Europe Joint Declaration (November 2024): Accelerating commitments to improve diabetes care and detection.
- UN High-Level Meeting on NCDs (September 2025): Expected to establish new frameworks for global NCD response.
Critical Gaps: Challenges in Policy and Practice
Despite positive strides, several key gaps persist in the Nordic region:
1. Workplace Integration Deficits
Systematic screening and intervention programs within the workplace remain underdeveloped. With working-age adults spending a third of their waking hours at work, integrating prediabetes prevention in corporate wellness programs could be a game-changer.
2. Health Equity Gaps
Swedish data reveals disparities in early-onset T2D, with incidence rates three times higher among immigrants and those with lower educational levels. This suggests that universal screening may not reach the highest-risk groups effectively.
3. Digital Health Underutilisation
While the Nordic region excels in digital health infrastructure, mobile apps and continuous glucose monitoring for prediabetes management remain underutilised at scale.
4. Post-Pandemic Surveillance Gaps
COVID-19 disrupted metabolic health across various age groups, with a 12% increase in Type 1 diabetes among individuals under 30 in Sweden. These disruptions require more targeted surveillance for autoimmune and metabolic diseases.
5. Policy Coherence Challenges
Only 5 out of 22 EU NCD prevention legislations directly address diabetes, highlighting a gap in addressing prediabetes as a distinct priority.
Strategic Recommendations for Nordic Business Leaders
- Adopt Systematic Screening: Implement tools like FINDRISC in occupational health settings, especially for sedentary or shift workers.
- Invest in Lifestyle Intervention: Partner with primary care providers to deliver evidence-based interventions.
- Address Health Equity: Target outreach to high-risk groups, including immigrant communities and lower-education populations.
- Leverage Digital Solutions: Invest in glucose monitoring and lifestyle coaching apps to intervene early and reduce healthcare costs in the long term.
- Advocate for Policy Alignment: Engage with national and EU diabetes strategies to ensure business perspectives influence public health planning.
Conclusion: Time for Action
Prediabetes is a growing but largely invisible threat to Nordic businesses. As global prevalence is expected to rise to 12.9% by 2050, the region’s relatively lower rates may not last without sustained intervention. Finland’s model shows that population-level prevention is possible, but it requires ongoing commitment, integration into occupational health, and innovative screening approaches. For Nordic businesses, the challenge is no longer whether to address prediabetes but how quickly they can implement proven interventions to avoid significant economic and human costs.
What’s Next: Upcoming Coverage
Stay tuned for “The Corporate Glucose Revolution: How Nordic Companies Are Rewiring Workplace Health.” We’ll explore how businesses are implementing continuous glucose monitoring and evaluate the return on investment for prediabetes intervention programs.
Connect with us: Share your organization’s experiences with workplace diabetes prevention programs. Contact our editorial team to contribute to ongoing coverage of this critical health issue.
Sources: International Diabetes Federation Diabetes Atlas (11th Edition, 2024), European Society of Cardiology economic burden studies, Swedish National Diabetes Register, Finnish National Institute for Health and Welfare, EU Joint Action JACARDI documentation.